Retatrutide Deep-Dive
Also known as: Triple Agonist · GIP/GLP-1/Glucagon Receptor Agonist · LY3437943
Retatrutide is a synthetic triple agonist at the GIP, GLP-1, and glucagon receptors. Researchers investigate the additive effect of glucagon-receptor activation — proposed to increase energy expenditure via thermogenesis — on top of the dual incretin mechanism shared with Tirzepatide. The compound is structurally modified for albumin binding and weekly dosing.
Plasma Half-Life
~6 days
Logarithmic scale · 6.0 d mapped
Tissue Residency
Sustained triple-receptor exposure throughout weekly dosing interval
Quick Facts
- Typical dose
- 2 mg → 12 mg weekly (titrated; protocols still emerging)
- Range
- 1 mg starter → 12 mg maintenance in published trials
- Route
- Subcutaneous injection, once weekly. Titration ladder is still being optimized in research contexts.
- Cycle pattern
- Continuous weekly administration. Long-term cycling protocols are still emerging as the compound is investigational.
- Primary evidence tier
- Clinical
Mechanism of Action
Retatrutide is a synthetic triple agonist at the GIP, GLP-1, and glucagon receptors. Researchers investigate the additive effect of glucagon-receptor activation — proposed to increase energy expenditure via thermogenesis — on top of the dual incretin mechanism shared with Tirzepatide. The compound is structurally modified for albumin binding and weekly dosing.
Researchers investigate Retatrutide in the broader context of the Metaboliccompound class. The compound's proposed relationship to underlying physiology is typically framed against the Insulin Resistance axis — a framework DoseCraft uses to organize research priorities across the 90+ compound library.
In the practitioner corpus that trains the DoseCraft AI copilot, Retatrutide's mechanism is repeatedly cross-referenced against its pharmacokinetic profile (plasma half-life ~6 days) because dosing cadence, stack selection, and cycling structure all derive from the PK window. This is the core difference between a static calculator and a PK-aware reasoning layer.
Pharmacokinetics
Plasma Half-Life (Logarithmic)
~6 days
Logarithmic scale · 6.0 d mapped
Tissue Residency
Sustained triple-receptor exposure throughout weekly dosing interval
Retatrutide has a plasma half-life of approximately ~6 days. This window is the primary driver of every downstream protocol decision: dosing frequency, stack overlap, cycling length, and the observable duration of subjective response.
Beyond the plasma window, sustained triple-receptor exposure throughout weekly dosing interval. This tissue-residency or functional-duration behavior is why practitioner protocols often deviate from what raw plasma half-life alone would suggest.
In the DoseCraft PK model, this compound is mapped onto the same decay-curve framework that powers the half-life visualizer in the app — every stack built in the Protocol Builder factors in the half-life overlap of Retatrutidealongside any co-administered compounds. Static calculators elsewhere ignore this; it's why the practitioner corpus consistently flags half-life literacy as a top-three safety variable.
From real clinicians · not PubMed abstracts
Practitioner Protocols
Practitioner Corpus
Sourced from clinician-validated protocols, bloodwork reviews, and cycle audits. Not PubMed. Not Reddit.
Retatrutide is the most-anticipated metabolic peptide in current research. Clinicians who run high-volume metabolic practices treat it as the leading-edge investigational compound, with the triple agonism producing the largest reported outcomes in published Phase II research. In protocol audits we've reviewed, practitioner stacking and cycling protocols are still emerging — most early adopters use Retatrutide solo with the same titration discipline applied to Semaglutide and Tirzepatide. The glucagon-receptor component introduces metabolic considerations that practitioners flag for monitoring in diabetic research contexts.
Dosing
2 mg → 12 mg weekly (titrated; protocols still emerging)
Subcutaneous injection, once weekly. Titration ladder is still being optimized in research contexts.
Cycle
Continuous weekly administration. Long-term cycling protocols are still emerging as the compound is investigational.
Evidence Breakdown
Every finding about Retatrutideis categorized across three independent evidence lanes. You always know what research tier you’re acting on.
- Phase II clinical trials demonstrated the largest published metabolic outcomes of any incretin compound to date. Phase III is in progress; FDA approval pending.
- Practitioner consensus treats Retatrutide as the leading-edge investigational metabolic compound. Stacking and long-term cycling protocols are still emerging.
- The triple-agonism mechanism (GIP + GLP-1 + glucagon) is novel; emerging research investigates cardiovascular, hepatic, and energy-expenditure applications.
Cycling & Stack Considerations
Cycling Protocol
Continuous weekly administration. Long-term cycling protocols are still emerging as the compound is investigational.
Common Stacks
- •Retatrutide solo (the dominant protocol; stacking research is preliminary)
- •Retatrutide + BPC-157 (gut-tolerance research)
Interactions & Overlap
- •Other incretin agonists (mechanistically overlapping; not co-administered)
- •Insulin and sulfonylureas (complex interaction due to glucagon mechanism)
- •Oral medications (slowed gastric emptying affects absorption)
Honest negatives · the part other trackers skip
Contraindications & Watch-Outs
Research Watch-Outs
- Personal or family history of medullary thyroid carcinoma
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- History of pancreatitis (relative contraindication; practitioner judgment)
- Pregnancy and lactation
- Glucagon-mediated glucose elevation requires monitoring in diabetic research contexts
Retatrutide FAQs
What is the half-life of Retatrutide?
Retatrutide has an approximate 6-day plasma half-life — between Tirzepatide (~5 days) and Semaglutide (~7 days). This supports once-weekly dosing.
Retatrutide vs Tirzepatide — which is better?
Phase II clinical research shows greater metabolic outcomes with Retatrutide than has been published for Tirzepatide. Phase III data is pending. Tirzepatide is dual-agonist (GIP + GLP-1); Retatrutide adds glucagon receptor activation.
What is the typical Retatrutide dose?
Published trials titrate 2 mg → 12 mg weekly, with the highest doses producing the largest outcomes. The optimal practitioner ladder is still being established.
What are the side effects of Retatrutide?
GI side effects (nausea, vomiting, diarrhea) mirror other incretin agonists. The glucagon component requires monitoring in diabetic research contexts due to glucagon-mediated glucose elevation considerations.
Is Retatrutide FDA approved?
Retatrutide is investigational and not FDA approved. Phase III trials are in progress. The compound is currently sold for research use only outside of approved trial settings.
Can Retatrutide be stacked with other peptides?
Stacking research is preliminary. Most early practitioner protocols use Retatrutide solo with BPC-157 co-administration occasionally appearing for gut-tolerance research.
How does the glucagon-receptor mechanism differ from GLP-1 only?
Glucagon-receptor activation is proposed to increase energy expenditure via thermogenesis and hepatic glucose mobilization. This adds a third mechanism on top of the dual incretin (insulin sensitization + appetite modulation) shared with Tirzepatide.
Related Compounds
Track your Retatrutide protocol in DoseCraft
The PK-aware protocol builder models ~6 days decay, checks stack overlap, and flags contraindications — built on the same practitioner corpus that powers this page.
See pricingFor research use only. Not for human consumption. Not evaluated by the FDA. Not intended to diagnose, treat, cure, or prevent any disease. Content on this page is educational and does not constitute medical advice, dosing guidance, or a protocol recommendation. Consult a qualified clinician before undertaking any research involving peptide compounds.